Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service

Table 1 Patient demographics and antiretroviral regimens

Characteristic	n (%) or median (IQR)
Sex
Male	70 (89)
Female	9 (11)
Age (years)	44 (34.5 to 53)
Cumulative TDF exposure (years)	3.5 (1.5 to 4.75)
Pre-switch TDF regimen
TDF/FTC/^†	38 (48)
TDF/FTC/RPV	18 (23)
TDF/FTC/EFV	15 (19)
TDF/FTC/E/COBI	8 (10)
Post-switch TAF regimen
TAF/FTC/^†	57 (72)
TAF/FTC/RPV	12 (15)
TAF/FTC/E/COBI	10 (13)

COBI cobicistat, E elvitegravir, EFV efavirenz, eGFR estimated glomerular filtration rate, FTC emtricitabine, RPV rilpivirine, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate
^†These regimens contained a third agent not otherwise listed in the table. In over three quarters of patients, both pre- and post-switch, the third agent was dolutegravir

ISSN: 1742-6405